SNSS News and Press, Viracta Therapeutics Inc Com From 12/05/19

Nano cap Sunesis Pharmaceuticals ( SNSS -24.2% ) slumps on a 20x surge in volume in apparent response to an abstract on an ongoing Phase 1/2 clinical trial evaluating BTK inhibitor vecabrutinib in patients with B cell blood cancers. The data will be presented at ASH in Sunday, December...

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced data from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leu...

Sunesis Pharmaceuticals, Inc. (SNSS) Q3 2019 Earnings Conference Call November 12, 2019 04:30 AM ET Executives Willie Quinn - Chief Financial Officer & Senior Vice President, Corporate Development Dayton Misfeldt - Interim Chief Executive Officer Judy Fox - Chief Scientific O...

Sunesis Pharmaceuticals (NASDAQ: SNSS ): Q3 GAAP EPS of -$0.06 beats by $0.03 . Cash and cash equivalents of $19.73M Press Release More news on: Sunesis Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,

Phase 1b/2 Trial of Vecabrutinib in 400 mg Cohort; Clinical Update at Upcoming ASH Annual Meeting  Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today r...

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 28 th Annual Credit Suisse Hea...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 61 st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida. The details for the post...

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, November 12 th , 2019 at 4:30 p.m. Eastern Time to discuss corporate updates and financial results for the third quarte...

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 26-30, 2019 in Boston, Massac...

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Dr. Nicole Onetto, M.D. has been appointed to the Sunesis Board of Directors. Dr. Onetto brings over 20 years of oncology drug development experience to the ...